肝细胞癌降期转化的治疗策略

袁声贤; 周伟平

doi:10.3969/j.issn.1001-5256.2020.02.002

肝细胞癌降期转化的治疗策略

DOI: 10.3969/j.issn.1001-5256.2020.02.002

海军军医大学附属东方肝胆外科医院肝外三科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1299
- HTML全文浏览量: 34
- PDF下载量: 349
- 被引次数: 0
出版历程
- 收稿日期: 2019-09-30
- 出版日期: 2020-02-20

Conversion therapy for hepatocellular carcinoma: Strategies and methods

Third Department of Hepatic Surgery,Eastern Hepatobiliary Surgery Hospital,Navy Medical University

摘要

摘要:
手术是肝细胞癌(HCC)最重要的根治性手段,但初诊时能获得手术切除的HCC患者不足30%。如何将不能切除转化为可根治性切除成为提高HCC生存率的重要方面,也是近年来的研究热点。目前,综合运用经肝动脉插管治疗、放射治疗、靶向治疗等方法让HCC实现降期,或者通过门静脉栓塞、联合肝脏隔断和门静脉结扎使残余肝体积快速增大,均可实现转化成功从而获得根治性切除的机会。但是,如何优化多种治疗模式,规范复杂性肝癌患者的多学科诊疗路径,提高手术切除的效率和安全性,仍需要进一步深入探讨和研究。
- 癌,肝细胞 /
- 化学栓塞,治疗性 /
- 放射疗法 /
- 分子靶向治疗
Abstract:
Surgery is the most important radical treatment for hepatocellular carcinoma( HCC),but less than 30% of HCC patients have the chance for radical surgery at initial diagnosis. How to transform unresectable tumor into the candidate of radical resection becomes an important way to improve the survival rate of HCC and has been a research hotspot in recent years. At present,comprehensive application of the therapies including hepatic artery catheterization,radiotherapy,and targeted therapy can achieve the downstaging of HCC,or portal vein embolization,liver partition,and portal vein ligation can rapidly increase residual liver volume; all these methods can realize successful conversion and help patients obtain the opportunity for radical resection. However,further exploration and studies are needed to investigate how to optimize a variety of treatment modes,standardize the multidisciplinary diagnosis and treatment of complex liver cancer,and improve the efficiency and safety of surgical resection.
- carcinoma,hepatocellular /
- chemoembolization,therapeutic /
- radiotherapy /
- molecular targeted therapy

HTML全文

参考文献(43)

[1] SCHLACHTERMAN A,CRAFT WW Jr,HILGENFELDT E,et al.Current and future treatments for hepatocellular carcinoma[J].World J Gastroenterol,2015,21(28):8478-8491.

[2] European Association for the Study of the Liver. EASL clinical practice guidelines:Drug-induced liver injury[J]. J Hepatol,2019,70(6):1222-1261.

[3] National Health and Family Planning Commission of the People’s Republic of China. Diagnosis,management,and treatment of hepatocellular carcinoma(V2017)[J]. J Clin Hepatol,2017,33(8):1419-1431.(in Chinese)中华人民共和国国家卫生和计划生育委员会．原发性肝癌诊疗规范(2017年版)[J]．临床肝胆病杂志，2017,33(8):1419-1431.

[4] PARIKH ND,WALJEE AK,SINGAL AG. Downstaging hepatocellular carcinoma:A systematic review and pooled analysis[J]. Liver Transpl,2015,21(9):1142-1152.

[5] LEI JY,YAN LN,WANG WT. Transplantation vs resection for hepatocellular carcinoma with compensated liver function after downstaging therapy[J]. World J Gastroenterol,2013,19(27):4400-4408.

[6] ZHANG Y,HUANG G,WANG Y,et al. Is salvage liver resection necessary for initially unresectable hepatocellular carcinoma patients downstaged by transarterial chemoembolization?Ten years of experience[J]. Oncologist,2016,21(12):1442-1449.

[7] JIANG L,LEI JY,WANG WT,et al. Immediate radical therapy or conservative treatments when meeting the Milan criteria for advanced HCC patients after successful TACE[J]. J Gastrointest Surg,2014,18(6):1125-1130.

[8] LEI JY,ZHONG JJ,YAN LN,et al. Response to transarterial chemoembolization as a selection criterion for resection of hepatocellular carcinomas[J]. Br J Surg,2016,103(7):881-890.

[9] LEE BH,LEE DS,CHO CW,et al. Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A[J]. World J Surg Oncol,2019,17(1):143.

[10] AFFONSO BB,GALASTRI FL,da MOTTA LEAL FILHO JM,et al. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or Downstaging[J]. World J Gastroenterol,2019,25(37):5687-5701.

[11] ALLARD MA,SEBAGH M,RUIZ A,et al. Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation?[J]. J Hepatol,2015,63(1):83-92.

[12] KULIK LM,ATASSI B,van HOLSBEECK L,et al. Yttrium-90microspheres(Thera Sphere)treatment of unresectable hepatocellular carcinoma:Downstaging to resection, RFA and bridge to transplantation[J]. J Surg Oncol,2006,94(7):572-586.

[13] IÑARRAIRAEGUI M,PARDO F,BILBAO JI,et al. Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma[J].Eur J Surg Oncol,2012,38(7):594-601.

[14] LABGAA I,TABRIZIAN P,TITANO J,et al. Feasibility and safety of liver transplantation or resection after transarterial radioembolization with Yttrium-90 for unresectable hepatocellular carcinoma[J]. HPB(Oxford),2019,21(11):1497-1504.

[15] LEWANDOWSKI RJ,KULIK LM,RIAZ A,et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma:Chemoembolization versus radioembolization[J]. Am J Transplant,2009,9(8):1920-1928.

[16] CHOS SH,SEONG J. Strategic application of radiotherapy for hepatocellular carcinoma[J]. Clin Mol Hepatol,2018,24(2):114-134.

[17] CHONG JU,CHOI GH,HAN DH,et al. Downstaging with localized concurrent chemoradiotherapy can identify optimal surgical candidates in hepatocellular carcinoma with portal vein tumor thrombus[J]. Ann Surg Oncol,2018,25(11):3308-3315.

[18] LI N,FENG S,XUE J,et al. Hepatocellular carcinoma with main portal vein tumor thrombus:A comparative study comparing hepatectomy with or without neoadjuvant radiotherapy[J]. HPB(Oxford),2016,18(6):549-556.

[19] WEI X,JIANG Y,ZHANG X,et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus:A randomized,open-label,multicenter controlled study[J]. J Clin Oncol,2019,37(24):2141-2151.

[20] YOSHIMOTO T,IMURA S,MORINE Y,et al. The outcome of sorafenib therapy on unresectable hepatocellular carcinoma:Experience of conversion and salvage hepatectomy[J]. Anticancer Res,2018,38(1):501-507.

[21] HE MK,ZOU RH,LI QJ,et al. Phase II study of sorafenib combined with concurrent hepatic arterial infusion of oxaliplatin,5-fluorouracil and leucovorin for unresectable hepatocellular carcinoma with major portal vein thrombosis[J]. Cardiovasc Intervent Radiol,2018,41(5):734-743.

[22] KUDO M,FINN RS,QIN S,et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:A randomised phase 3 non-inferiority trial[J]. Lancet,2018,391(10126):1163-1173.

[23] ZAANAN A,WILLIET N,HEBBAR M,et al. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma:A large multicenter AGEO study[J]. J Hepatol,2013,58(1):81-88.

[24] YEO W,MOK TS,ZEE B,et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil(PIAF)combination chemotherapy for unresectable hepatocellular carcinoma[J]. J Natl Cancer Inst,2005,97(20):1532-1538.

[25] LEUNG TW,PATT YZ,LAU WY,et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma[J]. Clin Cancer Res,1999,5(7):1676-1681.

[26] KASEB AO,SHINDOH J,PATT YZ,et al. Modified cisplatin/interferonα-2b/doxorubicin/5-fluorouracil(PIAF)chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate,resectability,and survival of initially unresectable hepatocellular carcinoma[J]. Cancer,2013,119(18):3334-3342.

[27] HUANG ZP,WANG ZH,LI Y,et al. Research advances in two-step hepatectomy combining liver partition with portal vein ligation[J]. Chin J Pract Surg,2018,38(4):456-459.(in Chinese)黄智平，王志恒，李曜，等．联合肝脏分隔和门静脉结扎的二步肝切除术研究进展[J]．中国实用外科杂志，2018,38(4):456-459.

[28] CHAN A,ZHANG WY,CHOK K,et al. ALPPS versus portal vein embolization for hepatitis-related hepatocellular carcinoma:A changing paradigm in modulation of future liver remnant before major hepatectomy[J]. Ann Surg, 2019.[Epub ahead of print]

[29] SCHADDE E,ARDILES V,SLANKAMENAC K,et al. ALPPS offers a better chance of complete resection in patients with primarily unresectable liver tumors compared with conventional-staged hepatectomies:Results of a multicenter analysis[J]. World J Surg,2014,38(6):1510-1519.

[30] WANG Z,PENG Y,HU J,et al. Associating liver partition and portal vein ligation for staged hepatectomy for unresectable hepatitis B virus-related hepatocellular carcinoma:A single center study of 45 patients[J]. Ann Surg,2018.[Epub ahead of print]

[31] PENG C,LI C,LIU C,et al. The outcome of the HCC patients underwent ALPPS:Retrospective study[J]. Medicine(Baltimore),2019,98(38):e17182.

[32] NADALIN S,CAPOBIANCO I,LI J,et al. Indications and limits for associating liver partition and portal vein ligation for staged hepatectomy(ALPPS). Lessons learned from 15 cases at a single centre[J]. Z Gastroenterol,2014,52(1):35-42.

[33] XIANG F,HU ZM. Chance and challenge of associating liver partition and portal vein ligation for staged hepatectomy[J].Hepatobiliary Pancreat Dis Int,2019,18(3):214-222.

[34] CHIA DKA,YEO Z,LOH SEK,et al. ALPPS for hepatocellular carcinoma is associated with decreased liver remnant growth[J]. J Gastrointest Surg,2018,22(6):973-980.

[35] TRUANT S,BAILLET C,DESHORGUE AC,et al. Contribution of hepatobiliary scintigraphy in assessing ALPPS most suited timing[J]. Updates Surg,2017,69(3):411-419.

[36] MELANDRO F,GIOVANARDI F,HASSAN R,et al. Minimally invasive approach in the setting of ALPPS procedure:A systematic review of the literature[J]. J Gastrointest Surg,2019,23(9):1917-1924.

[37] SIRIWARDANA RC,LO CM,CHAN SC,et al. Role of portal vein embolization in hepatocellular carcinoma management and its effect on recurrence:A case-control study[J]. World J Surg,2012,36(7):1640-1646.

[38] YOO H,KIM JH,KO GY,et al. Sequential transcatheter arterial chemoembolization and portal vein embolization versus portal vein embolization only before major hepatectomy for patients with hepatocellular carcinoma[J]. Ann Surg Oncol,2011,18(5):1251-1257.

[39] TUSTUMI F,ERNANI L,COELHO FF,et al. Preoperative strategies to improve resectability for hepatocellular carcinoma:A systematic review and meta-analysis[J]. HPB(Oxford),2018,20(12):1109-1118.

[40] PENG SY,WANG XA,HUANG CY,et al. Evolution of associating liver partition and portal vein ligation for staged hepatectomy:Simpler,safer and equally effective methods[J]. World J Gastroenterol,2017,23(23):4140-4145.

[41] GARLIPP B,de BAERE T,DAMM R,et al. Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization[J]. Hepatology,2014,59(5):1864-1873.

[42] GABR A,ABOUCHALEH N,ALI R,et al. Outcomes of surgical resection after radioembolization for hepatocellular carcinoma[J]. J Vasc Interv Radiol,2018,29(11):1502-1510.

[43] CHENG H,SUN G,CHEN H,et al. Trends in the treatment of advanced hepatocellular carcinoma:Immune checkpoint blockade immunotherapy and related combination therapies[J]. Am J Cancer Res,2019,9(8):1536-1545.

施引文献

资源附件(0)

访问统计